Optimizing the use of biological therapy in patients with inflammatory bowel disease

DSpace/Manakin Repository

Optimizing the use of biological therapy in patients with inflammatory bowel disease

Citable link to this page

 

 
Title: Optimizing the use of biological therapy in patients with inflammatory bowel disease
Author: Moss, Alan C.
Citation: Moss, Alan C. 2015. “Optimizing the use of biological therapy in patients with inflammatory bowel disease.” Gastroenterology Report 3 (1): 63-68. doi:10.1093/gastro/gou087. http://dx.doi.org/10.1093/gastro/gou087.
Full Text & Related Files:
Abstract: Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved—or are in development for—both Crohn’s disease (CD) and ulcerative colitis (UC). Early use of these agents taught clinicians that induction and maintenance therapy, coupled with immunomodulator agents, reduced the immunogenicity of these agents, and led to sustained remission in many patients. More recent data has demonstrated that, through dose adjustments, optimizing serum drug levels may also provide more durable maintenance of remission, and improved mucosal healing. This review examines clinical practices that may enhance clinical outcomes from biological therapy in IBD.
Published Version: doi:10.1093/gastro/gou087
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324872/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351371
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters